Sunshine Biopharma, Inc. (SBFM)
After hours:
| Previous Close | 0.8290 |
| Open | 0.8054 |
| Bid | 0.7931 x 900 |
| Ask | 0.8112 x 1000 |
| Day's Range | 0.7862 - 0.8299 |
| 52 Week Range | 0.7010 - 9.8700 |
| Volume | |
| Avg. Volume | 1,023,362 |
| Market Cap | 15.108M |
| Beta (5Y Monthly) | -1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2140 |
| Earnings Date | Aug 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
We're Hopeful That Sunshine Biopharma (NASDAQ:SBFM) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Sunshine Biopharma Files Its Second Quarter Report With the SEC
Company Reports Significant Increase in Cash on Hand as a Result of Recent FinancingsMONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed its 2022 second quarter report with the Securities and Exchange Commission. The Report shows that the Company had Cash & Cash Equivalents of $41,727,775 as of June 3
- GlobeNewswire
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway. The development of the Co
